10-Q Filing

Xenetic Biosciences, Inc. CIK: 1534525 Q3 2022

Filing Information

Form Type	10-Q
Accession Number	`0001683168-22-007447`
Period End Date	20220930
Filing Date	20221109
Fiscal Year	2022
Fiscal Period	Q3
XBRL Instance	xenetic_i10q-093022_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 48 Income Statement 56 Cash Flow Statement 46 Stockholders Equity 31

Balance Sheet 48 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Cash	`Cash`	$18.24M	USD	Point-in-time
Cash	`Cash`	$13.85M	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$479.40K	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$319.10K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$14.17M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$18.72M	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$1.41M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$1.09M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	50.00M	shares	Point-in-time
Total assets	`Assets`	$15.57M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	13.47M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	14.34M	shares	Point-in-time
Total assets	`Assets`	$19.82M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	14.32M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	13.44M	shares	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$202.78K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$362.47K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$848.08K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$1.06M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.05M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.42M	USD	Point-in-time
Total liabilities	`Liabilities`	$1.05M	USD	Point-in-time
Total liabilities	`Liabilities`	$1.42M	USD	Point-in-time
Commitments and contingencies (Note 10)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 10)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.001 par value; 50,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 14,343,587 and 13,466,603 shares issued as of September 30, 2022 and December 31, 2021, respectively; 14,316,596 and 13,439,612 shares outstanding as of September 30, 2022 and December 31, 2021, respectively	`CommonStockValue`	$14.34K	USD	Point-in-time
Common stock, $0.001 par value; 50,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 14,343,587 and 13,466,603 shares issued as of September 30, 2022 and December 31, 2021, respectively; 14,316,596 and 13,439,612 shares outstanding as of September 30, 2022 and December 31, 2021, respectively	`CommonStockValue`	$13.46K	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$207.15M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$205.95M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-187.62M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-182.55M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$253.73K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$253.73K	USD	Point-in-time
Treasury stock	`TreasuryStockValue`	$5.28M	USD	Point-in-time
Treasury stock	`TreasuryStockValue`	$5.28M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$14.52M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$20.16M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$15.19M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$18.39M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$9.95M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$12.22M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$15.57M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$19.82M	USD	Point-in-time

Income Statement 56 line items

Line Item	Tag	Value	Unit	Period
Earnings Per Share, Basic	`EarningsPerShareBasic`	$-0.41	USD	3 Qtrs
Earnings Per Share, Basic	`EarningsPerShareBasic`	$-0.06	USD	1 Quarter
Earnings Per Share, Basic	`EarningsPerShareBasic`	$-0.13	USD	1 Quarter
Earnings Per Share, Basic	`EarningsPerShareBasic`	$-0.36	USD	3 Qtrs
Royalty revenue	`RoyaltyIncomeNonoperating`	$349.27K	USD	1 Quarter
Royalty revenue	`RoyaltyIncomeNonoperating`	$414.25K	USD	1 Quarter
Earnings Per Share, Diluted	`EarningsPerShareDiluted`	$-0.06	USD	1 Quarter
Earnings Per Share, Diluted	`EarningsPerShareDiluted`	$-0.36	USD	3 Qtrs
Earnings Per Share, Diluted	`EarningsPerShareDiluted`	$-0.41	USD	3 Qtrs
Royalty revenue	`RoyaltyIncomeNonoperating`	$828.09K	USD	3 Qtrs
Royalty revenue	`RoyaltyIncomeNonoperating`	$1.22M	USD	3 Qtrs
Earnings Per Share, Diluted	`EarningsPerShareDiluted`	$-0.13	USD	1 Quarter
Weighted Average Number of Shares Outstanding, Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	13.94M	shares	3 Qtrs
Weighted Average Number of Shares Outstanding, Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	10.16M	shares	1 Quarter
Weighted Average Number of Shares Outstanding, Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	14.32M	shares	1 Quarter
Total revenue	`Revenues`	$349.27K	USD	1 Quarter
Total revenue	`Revenues`	$828.09K	USD	3 Qtrs
Total revenue	`Revenues`	$1.22M	USD	3 Qtrs
Weighted Average Number of Shares Outstanding, Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	9.22M	shares	3 Qtrs
Total revenue	`Revenues`	$414.25K	USD	1 Quarter
Weighted Average Number of Shares Outstanding, Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	14.32M	shares	1 Quarter
Weighted Average Number of Shares Outstanding, Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	10.16M	shares	1 Quarter
Weighted Average Number of Shares Outstanding, Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	9.22M	shares	3 Qtrs
Weighted Average Number of Shares Outstanding, Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	13.94M	shares	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$780.15K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.93M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$3.58M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$398.80K	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$863.23K	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$2.77M	USD	3 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$945.12K	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$2.80M	USD	3 Qtrs
Total operating costs and expenses	`OperatingExpenses`	$6.37M	USD	3 Qtrs
Total operating costs and expenses	`OperatingExpenses`	$1.73M	USD	1 Quarter
Total operating costs and expenses	`OperatingExpenses`	$1.26M	USD	1 Quarter
Total operating costs and expenses	`OperatingExpenses`	$4.70M	USD	3 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-847.79K	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-5.15M	USD	3 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-3.87M	USD	3 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-1.38M	USD	1 Quarter
Other expense	`OtherNonoperatingIncomeExpense`	$-2.91K	USD	1 Quarter
Other expense	`OtherNonoperatingIncomeExpense`	$-1.78K	USD	3 Qtrs
Other expense	`OtherNonoperatingIncomeExpense`	$-2.58K	USD	3 Qtrs
Other expense	`OtherNonoperatingIncomeExpense`	$-1.71K	USD	1 Quarter
Interest income, net	`InterestIncomeExpenseNet`	$71.03K	USD	3 Qtrs
Interest income, net	`InterestIncomeExpenseNet`	$45.48K	USD	1 Quarter
Interest income, net	`InterestIncomeExpenseNet`	$28.03K	USD	1 Quarter
Interest income, net	`InterestIncomeExpenseNet`	$87.34K	USD	3 Qtrs
Total other income	`NonoperatingIncomeExpense`	$84.76K	USD	3 Qtrs
Total other income	`NonoperatingIncomeExpense`	$69.24K	USD	3 Qtrs
Total other income	`NonoperatingIncomeExpense`	$25.12K	USD	1 Quarter
Total other income	`NonoperatingIncomeExpense`	$43.77K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-3.80M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-1.35M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-5.07M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-804.02K	USD	1 Quarter

Cash Flow Statement 46 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-3.80M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-1.35M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-5.07M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-804.02K	USD	1 Quarter
Acquired in-process research and development	`ResearchAndDevelopmentInProcess`	$1.30M	USD	3 Qtrs
Acquired in-process research and development	`ResearchAndDevelopmentInProcess`	-	USD	3 Qtrs
Amortization of right of use asset	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$26.20K	USD	3 Qtrs
Amortization of right of use asset	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$27.04K	USD	3 Qtrs
Share-based expense	`EmployeeBenefitsAndShareBasedCompensation`	$392.83K	USD	3 Qtrs
Share-based expense	`EmployeeBenefitsAndShareBasedCompensation`	$297.34K	USD	3 Qtrs
Prepaid expenses and other	`IncreaseDecreaseInAccountsAndOtherReceivables`	$62.48K	USD	3 Qtrs
Prepaid expenses and other	`IncreaseDecreaseInAccountsAndOtherReceivables`	$-133.25K	USD	3 Qtrs
Other long-term assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$313.92K	USD	3 Qtrs
Other long-term assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$-105.56K	USD	3 Qtrs
Accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$157.52K	USD	3 Qtrs
Accounts payable, accrued expenses and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-370.25K	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-3.90M	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-3.28M	USD	3 Qtrs
Net cash paid to acquire in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	$500.00K	USD	3 Qtrs
Net cash paid to acquire in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	-	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	-	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-500.00K	USD	3 Qtrs
Net proceeds from issuance of common stock and warrants	`ProceedsFromIssuanceOfCommonStock`	-	USD	3 Qtrs
Net proceeds from issuance of common stock and warrants	`ProceedsFromIssuanceOfCommonStock`	$11.45M	USD	3 Qtrs
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$3.68K	USD	3 Qtrs
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	-	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	-	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$11.45M	USD	3 Qtrs
Net change in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$8.18M	USD	3 Qtrs
Net change in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$-4.40M	USD	3 Qtrs
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$11.53M	USD	Point-in-time
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$13.85M	USD	Point-in-time
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$19.70M	USD	Point-in-time
Cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$18.24M	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$11.53M	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$13.85M	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$19.70M	USD	Point-in-time
Cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$18.24M	USD	Point-in-time
Cash paid for interest	`InterestPaidNet`	-	USD	3 Qtrs
Cash paid for interest	`InterestPaidNet`	-	USD	3 Qtrs
Issuance of common stock to acquire in-process research and development	`IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment`	$805.00K	USD	3 Qtrs
Issuance of common stock to acquire in-process research and development	`IssuanceOfCommonStockToAcquireInprocessResearchAndDevelopment`	-	USD	3 Qtrs
Issuance of common stock to vendor	`IssuanceOfCommonStockToVendor`	$7.00	USD	3 Qtrs
Issuance of common stock to vendor	`IssuanceOfCommonStockToVendor`	-	USD	3 Qtrs
Issuance of common stock from cashless exercise of purchase warrants	`IssuanceOfCommonStockFromCashlessExerciseOfPurchaseWarrants`	$4.00	USD	3 Qtrs
Issuance of common stock from cashless exercise of purchase warrants	`IssuanceOfCommonStockFromCashlessExerciseOfPurchaseWarrants`	$2.00	USD	3 Qtrs

Stockholders Equity 31 line items

Line Item	Tag	Value	Unit	Period
Beginning balance, value	`StockholdersEquity`	$14.52M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$20.16M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$15.19M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$18.39M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$9.95M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$12.22M	USD	Point-in-time
Issuance of common stock and warrants, net of issuance costs	`StockIssuedDuringPeriodValueNewIssues`	$11.45M	USD	1 Quarter
Issuance of common stock and warrants, net of issuance costs	`StockIssuedDuringPeriodValueNewIssues`	$11.45M	USD	3 Qtrs
Issuance of common stock and warrants, net of issuance costs, shares	`StockIssuedDuringPeriodSharesNewIssues`	850,000.00	shares	Point-in-time
Exercise of pre-funded warrants	`ExerciseOfPrefundedWarrants`	$3.68K	USD	1 Quarter
Exercise of pre-funded warrants	`ExerciseOfPrefundedWarrants`	$3.68K	USD	3 Qtrs
Issuance of common stock in connection with purchase of in-process research and development	`IssuanceOfCommonStockInConnectionWithPurchaseOfInprocessResearchAndDevelopment`	$805.00K	USD	3 Qtrs
Share-based expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$392.83K	USD	3 Qtrs
Share-based expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$111.13K	USD	1 Quarter
Share-based expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$137.36K	USD	1 Quarter
Share-based expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$297.34K	USD	3 Qtrs
Exercise of purchase warrants	`ExerciseOfPurchaseWarrantsValue`	-	USD	1 Quarter
Exercise of purchase warrants	`ExerciseOfPurchaseWarrantsValue`	-	USD	3 Qtrs
Exercise of purchase warrants	`ExerciseOfPurchaseWarrantsValue`	-	USD	3 Qtrs
Issuance of common stock to vendor	`StockIssuedDuringPeriodValueOther`	-	USD	3 Qtrs
Issuance of common stock to vendor	`StockIssuedDuringPeriodValueOther`	-	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-3.80M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-1.35M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-5.07M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-804.02K	USD	1 Quarter
Ending balance, value	`StockholdersEquity`	$14.52M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$20.16M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$15.19M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$18.39M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$9.95M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$12.22M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.